Study of CDX-3379, a Human Monoclonal Antibody Targeting ERBB3, in Combination With the MEK Inhibitor, Trametinib, in Patients With Advanced Stage NRAS Mutant and BRAF/NRAS Wildtype (WT) Melanoma

Phase 1/2 Terminated 3 enrolled NYU Langone Health Celldex Therapeutics · collab

Non-randomizedParallel-groupOpen-labelTreatment

Summary

The main goal of this study is to test if it is safe and effective to give CDX-3379 together to treat advanced melanoma in patients with the NRAS mutation and BRAF/NRAS wildtype.

Timeline

Start: 2018-07-06
Primary completion: 2018-09-26
Completion: 2018-09-26

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	CDX-3379	Unknown	15 mg/kg	Intravenous
Subject	Trametinib	Small molecule	1 mg	—

Study of CDX-3379, a Human Monoclonal Antibody Targeting ERBB3, in Combination With the MEK Inhibitor, Trametinib, in Patients With Advanced Stage NRAS Mutant and BRAF/NRAS Wildtype (WT) Melanoma

Summary

Timeline

Drugs

Indications